-
PK and PD of the Small Interfering Ribonucleic Acid (
#siRNA), Givosiran, in Patients with Acute Hepatic#Porphyria$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#RNAi@RNAi_papers@JMaraganore@Alnylam https://www.ncbi.nlm.nih.gov/pubmed/31994716 pic.twitter.com/X6jFMv339V
-
Good luck with that. At least for RNAi, it was industry that took all of the risk and did 98% of work to turn it into a medical reality.
$ALNY$ARWR$DRNA$SLN https://twitter.com/MikeBloomberg/status/1221873047583576065 … -
Jefferies EU
#biotech 2020 outlook Top picks:$GMAB$UCB$ONCO Possible winners from binary events:$NWRN$ERYP$SKIN Least preferred:$GLPG$LUN.CO ($HLUYY$HLUKF ) Other mentions:$ACIU$IDIA$IDRSF$IVA$IPSEY$ORY$SLN$STX$FARN$PHMMF$RNUGF$AVDL$VELO$POXEL$KDSpic.twitter.com/LHbODG7W8m
Prikaži ovu nit -
$SLN Silence Therapeutics once specialized in using lipoplexes to deliver systemically to lung. But that was in past, now GalNAc-focused. I bet, Wuhan coronavirus-targeting RNAi triggers being produced by some as we speak.#coronavirus$XBIPrikaži ovu nit -
A good 2019 review of the public EU
#biotech landscape and a 2020 outlook from@BertrandBio &@biotechradar_eu$GLPG$ARGX$GMAB$ACE$ALZ$SLN$MNK$PHMMF$FARN$STX$ZEAL$OZYMF$ORPHA$MOR$OXB$GNFT$DBVT$IVA$LYS$KDS$POXEL Article: https://biotechradar.eu/european-listed-biotech-landscape-2019-review-and-outlook-for-2020/ …pic.twitter.com/BGzGPHFPqZ
Prikaži ovu nit -
Don't miss this Interview with the 2019 OTS Lifetime Achievement Award Winner Muthiah (Mano) Manoharan!
$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#siRNA#RNAi@RNAi_papers@JMaraganore@Alnylam@ArrowheadPharma@SilenceTheraPlc@DicernaPharma https://www.oligotherapeutics.org/interview-with-mano-manoharan/ …pic.twitter.com/Lx50u0tCAV
-
Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
$ARWR$DRNA$ALNY$ABUS$SLN$AMGN@OliXPharmaceut1#siRNA#RNAi@RNAi_papers@SilenceTheraPlc@DicernaPharma https://www.ncbi.nlm.nih.gov/pubmed/31821125 pic.twitter.com/tq5dglYyfU
-
He didn’t even get a platform with it. I would rather have a pre clinical lp(a) programme and an RNAi platform for $1bn. Like
$SLN
-
Silence Therapeutics unveils Takeda deal, plans to create US subsidiary
$SLN$TAKhttps://www.proactiveinvestors.co.uk/companies/news/910073/silence-therapeutics-unveils-takeda-deal-and-unveils-plans-to-create-us-subsidiary-910073.html … -
$SLN Silence Therapeutics provides business update - Signed tech eval deal with$TAK for siRNA molecules for undisclosed target - Exploring multiple BD deals with large#pharma - Opening US subsidiary in 2020$ANLY$DRNA$ABUS$MDCO$ARWR$NVS$NVO PR: https://www.silence-therapeutics.com/media/1982/200107_silence_therapeutics_announces_business_update.pdf …Prikaži ovu nit -
-
-
$ARWR$SLN http://www.onlinejacc.org/content/74/24/2982 … here is link to article, podcast too. -

Silence Therapeutics $SLN YTD perf is now 4-digit, with... +1025%

Well done to the long bulls. -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
